Buch, Englisch, Band 112, 230 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 376 g
Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 ¿ November 1, 1989
Buch, Englisch, Band 112, 230 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 376 g
Reihe: Developments in Cardiovascular Medicine
ISBN: 978-1-4612-8809-1
Verlag: Springer US
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
I. Approaches and Methods to Studying Antihypertensive Drugs.- 1. New concepts in antihypertensive drug therapy.- 2. Is ambulatory blood pressure monitoring required to define the hypertensive patient and to detect efficacy?.- 3. What vascular effects should be measured in antihypertensive drug research?.- 4. Is it necessary to demonstrate changes in left ventricular hypertrophy in the evaluation of antihypertensive drugs?.- 5. Clinical trials of antihypertensive agents.- 6. How does one define dose-duration of an antihypertensive drug? What is the role of non-Mem and the Peak/Through measurement.- II. What Should be Required for FDA Approvability of a New Antihypertensive Drug?.- 7. What have we learned from prior clinical trials of antihypertensive drug therapy?.- 8. Are specific studies in elderly patients required for FDA approvability of a new antihypertensive drug?.- 9. Do we need any more antihypertensive drugs: The validity of a change in blood pressure as the only endpoint for approvability?.- 10. The cost and time to develop a new antihypertensive drug depending upon the endpoint.- III. Surrogate Endpoints to Define Risk VS. Benefits.- 11. What should be required for FDA approvability of a new antihypertensive drug? What is the FDA’s viewpoint?.- 12. Are there valid surrogate endpoints for mortality that can be used to evaluate the effects of antiarrhythmic drug therapy?.- 13. How to demonstrate the efficacy of a new drug for the treatment of chronic heart failure.- 14. Testing the relationship between cholesterol lowering and cardiovascular disease — past, present, and prospects.- Participant List.